Activity Overview
Low-grade serous ovarian cancer (LGSOC) is a rare, distinct subtype of epithelial ovarian cancer that disproportionately affects younger women and remains challenging to treat due to its slow progression, high recurrence risk, and limited responsiveness to chemotherapy. With the rapidly evolving landscape of targeted therapies—including recent advances in RAF/MEK pathway inhibitors—clinicians face increasing complexity in diagnosis, molecular interpretation, and treatment selection, highlighting a significant unmet educational need.
To address these gaps, this program uses the Cases and Conversations™ format to deliver an interactive, case-based discussion led by expert faculty. Presented adjunct to the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held in San Juan, Puerto Rico, this symposium provides an ideal forum for translating new clinical trial data, molecular insights, and evolving standards of care into real-world practice. The format is designed to help clinicians contextualize emerging evidence, compare decision-making with peers and experts, and strengthen their ability to personalize therapy for patients with LGSOC.
This educational activity is an archive of the live presentation held on Sunday, April 12, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward attendees of the SGO Annual Meeting on Women’s Cancer, including medical oncologists, radiation oncologists, pathologists, obstetrician/gynecologists, advanced practice providers, nurses, pharmacists, trainees, and other health care providers involved in the management of patients with ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better
prepared to:
- Describe key distinguishing features of low-grade serous ovarian cancer (LGSOC) to ensure accurate diagnosis
- Examine the current standard of care for LGSOC, focusing on the roles of surgery and adjuvant systemic therapies, including chemotherapy, targeted therapies, and hormonal therapies
- Develop personalized treatment plans for patients with recurrent LGSOC based on patient- and disease-specific characteristics
Rachel N. Grisham, MD
Associate Attending Physician, Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology
Memorial Sloan Kettering Westchester
West Harrison, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem Oncology
David M. Gershenson, MD
Professor, Department of Gynecologic Oncology and Reproductive
Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Fee for Service Recipient: Verastem Oncology; Grant/Research Funding: STAAR Ovarian Cancer Foundation; Ownership interests in publicly traded companies: Bristol Myers Squibb, Johnson & Johnson, Procter & Gamble; Royalty or Patent Benefits: Elsevier UpToDate; Executive Role: Chair, International Consortium for Low-Grade Serous Ovarian Cancer
Ursula Matulonis, MD
Professor of Medicine, Harvard Medical School
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Co-Leader, Ovarian Cancer SPORE Grant
Co-Leader, Dana-Farber/Harvard Cancer Center GYN Program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Daiichi Sankyo, Day One, GSK, Immunogen, NextCure, Novartis, Tango, Whitehawk; Data Safety Monitoring Board: Daiichi Sankyo, MacroGenics, Mural Oncology, Symphogen
David M. O’Malley, MD
Professor of Obstetrics and Gynecology
Director and John G. Boutselis Chair, Division of Gynecologic
Oncology
The Ohio State University
James Comprehensive Cancer Center
Columbus, OH
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, AstraZeneca, BeOne, Corcept Therapeutics, DSI, Duality Bio, Eli Lilly, GenMab, GlaxoSmithKline, GOG Foundation, Merck & Co, Merck Sharp & Dohme Corp., Novocure, Pfizer, Regeneron Pharmaceuticals, Inc., Verastem, Inc.; Grant/Research Funding: Institution receives funds: AbbVie, Advaxis, Agenus,Inc, Alkermes, Aravive, Inc., Arcus Biosciences, Inc., AstraZeneca, BeiGene USA,Inc.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here